Piramal Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Piramal Pharma is strategically transitioning towards higher-margin segments, particularly sterile injectables and inhalation anesthesia, as management emphasizes operational excellence and capacity expansion. Recent earnings calls highlight broad-based growth across its CDMO and consumer healthcare segments, supported by a robust pipeline and a focus on premiumization. Vista's financial outlook reflects this positive momentum, forecasting early recovery in revenue growth and stable margins, underpinned by a disciplined approach to capital allocation and pricing strategies. However, the company faces competitive pressures from Chinese generics and potential delays in customer order conversions, which could impact short-term performance. The broader industry context remains supportive, with improving pricing power and a favorable growth trajectory for Indian CDMOs. Over the next 12-24 months, key opportunities include leveraging digital channels and expanding ADC capabilities, while watchpoints include regulatory complexities and inflationary pressures on input costs
Why We Like This Stock
- Management's focus on higher-margin segments and operational excellence is expected to drive revenue growth
- Broad-based growth across CDMO and consumer healthcare segments supports a positive financial outlook
- Improving pricing power in the industry enhances margin potential for Piramal Pharma
Things To Watch Out For
- Competitive pressures from Chinese generics may hinder market share and pricing power
- Delays in converting RFPs into commercial orders could impact revenue recovery timelines
- Inflationary pressures on input costs may challenge profitability despite stable margins
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 8,171 | 9,151 | 8,869 | 9,849 | 11,228 |
| Profit Before Tax (Cr.) | 238 | 405 | 20 | 260 | 355 |
| PBT Margin | 2.9% | 4.4% | 0.2% | 2.6% | 3.2% |
| Net Profit (Cr.) | 18 | 111 | -261 | 195 | 266 |
| Earnings Per Share | 0.1 | 0.8 | -2.0 | 1.5 | 2.0 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Jeffries | ▲ Buy | 235 | 27-Aug-2026 |
| Goldman Sachs | ▲ Buy | 250 | 31-Jul-2026 |
| ICICI Securities | ▲ Buy | 245 | 31-Jul-2026 |
| HDFC Securities | ▲ Buy | 240 | 30-Jul-2026 |
| Motilal Oswal | ▲ Buy | 230 | 30-Jul-2026 |
Company Overview
Show Company Profile
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.